BPDCN International Registry shared a post on Linkedin:
“Mutational profiling has completely reshaped how we think about BPDCN biology and clonal evolution. Epigenetic regulators keep showing up again and again in genomic studies, often as early/ancestral events that shape the disease course.
In your practice or reading, which mutations have you found most striking or clinically relevant in BPDCN-those that really changed how you think about prognosis or potential targets? Share your thoughts in the comments.”
Other articles about BPDCN on OncoDaily.